135719-28-7

Basic information

• Product Name: silicon phthalocyanine
• Synonyms: silicon phthalocyanine;Nsc676418;Silicone phthalocyanine;Silicon,[[3-(dimethylamino)propyl]dimethylsilanolato-kO]hydroxy[29H,31H-phthalocyaninato(2-)-kN29,kN30,kN31,kN32]-, (OC-6-23)- (9CI)
• CAS NO: 135719-28-7
• Molecular Formula: C₃₉H₃₅N₉O₂Si₂
• Molecular Weight: 716.93724
• Mol File: 135719-28-7.mol

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• CAS DataBase Reference: silicon phthalocyanine(CAS DataBase Reference)
• NIST Chemistry Reference: silicon phthalocyanine(135719-28-7)
• EPA Substance Registry System: silicon phthalocyanine(135719-28-7)

Safety Data

• Hazardous Substances Data: 135719-28-7(Hazardous Substances Data)

Usage

Uses

Used in Dye and Pigment Industry:
Silicon phthalocyanine is utilized as a dye and pigment due to its vibrant blue color, providing a stable and long-lasting coloration for various applications.
Used in Semiconductor Industry:
In the semiconductor industry, silicon phthalocyanine serves as a material for electronic devices, capitalizing on its thermal and chemical stability to enhance device performance and reliability.
Used in Photovoltaic Cells:
Silicon phthalocyanine is employed in the development of photovoltaic cells, leveraging its high absorption in the near-infrared region to improve the efficiency of solar energy conversion.
Used in Ink Industry:
silicon phthalocyanine is used as an ink ingredient, offering a consistent and durable color for printing applications.
Used in Medical Imaging:
Silicon phthalocyanine is used as a contrast agent in medical imaging, taking advantage of its near-infrared absorption properties to enhance the visualization of internal structures.
Used in Photodynamic Therapy:
In the medical field, silicon phthalocyanine is applied in photodynamic therapy, where its light-absorbing properties are used to target and treat specific cells or tissues.
Used in Advanced Materials and Technologies:
Due to its unique chemical structure, silicon phthalocyanine is used as a base for the development of new materials and technologies, with its properties being modified to suit specific applications and innovations.

InChI:InChI=1/C33H17N7.C7H18NOSi.H2O.Si/c1-3-11-20-18(9-1)26-17-27-19-10-2-4-12-21(19)29(35-27)37-31-23-14-6-8-16-25(23)33(39-31)40-32-24-15-7-5-13-22(24)30(38-32)36-28(20)34-26;1-8(2)6-5-7-10(3,4)9;;/h1-17H;5-7H2,1-4H3;1H2;/q-2;-1;;+4/p-1

Synthetic route

CH3SiPcOSi(CH3)2(CH2)3N(CH3)2 → phthalocyanine 4 (135719-28-7)

Conditions	Yield
With water; triethylamine In toluene for 0.25h; Irradiation with an incandescent light;	96%

C42H41N9OSSi2 (1621068-23-2) → phthalocyanine 4 (135719-28-7)

Conditions	Yield
With methanol Quantum yield; UV-irradiation;

Pc 12 → phthalocyanine 4 (135719-28-7)

Conditions	Yield
With trichloroacetic acid In dichloromethane at 20℃; for 5h;	392 mg

phthalocyanine 4 (135719-28-7) + methyl iodide (74-88-4) → HOSiPcOSi(CH3)2(CH2)3N(CH3)3+I- (142084-57-9)

Conditions	Yield
In benzene for 1.5h; Heating / reflux;	81%

methanol (67-56-1) + phthalocyanine 4 (135719-28-7) → C40H37N9O2Si2

Conditions	Yield
With pyridine for 0.5h; Reflux;	80%

phthalocyanine 4 (135719-28-7) → HOSiPcOSi(CH3)2(CH2)3N(CH3)2 hydrochloride (868157-43-1)

Conditions	Yield
With hydrogenchloride In methanol; ethanol; water for 0.166667h;	67%

phthalocyanine 4 (135719-28-7) + 2-oxo-propionic acid (127-17-3) → HOSiPcOSi(CH3)2(CH2)3N(CH3)2 pyruvate (868157-44-2)

Conditions	Yield
In dichloromethane for 1h;	59%

Upstream product

• 1621068-23-2 C₄₂H₄₁N₉OSSi₂ 

Related news

Benzyl ester dendrimer silicon phthalocyanine (cas 135719-28-7) based polymeric nanoparticle for in vitro photodynamic therapy of glioma08/17/2019

A novel second generation benzyl ester dendrimer silicon phthalocyanine (D-SiPc) was synthesized and encapsulated into amphiphilic block copolymers to form polymeric nanoparticles ([email protected]). The cellular uptake and subcellular localization of [email protected] in U251 glioma cells were...detailed

Relevant articles and documents

Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy

A photoprecursor Pc 227 is covalently bound onto gold nanoparticles (Au NPs) to produce the known photodynamic therapy (PDT) drug Pc 4 upon 660 nm photoirradiation. The photochemical formation of the photoproduct Pc 4 is identified by spectroscopy, chromatography, and mass spectrometry and its PDT efficacy is equal to Pc 4 when administered non-covalently by Au NPs, with the added benefit of improved covalent delivery and targeted NIR-triggered release from the covalent Pc 227-Au NP conjugate, while during transport the attached Pc 227 is quenched by the Au NP and PDT inactivated.

Synthesis, properties and drug potential of the photosensitive alkyl- and alkylsiloxy-ligated silicon phthalocyanine Pc 227

The photosensitive, alkyl- and alkylsiloxy-ligated silicon phthalocyanine, SiPc[(CH2)3SH][OSi(CH3)2(CH2)3N(CH3)2], Pc 227, has been prepared and characterized. This phthalocyanine yields the experimental photodynamic therapy (PDT) drug Pc 4, SiPc[OH][OSi(CH3)2(CH2)3N(CH3)2], when irradiated with red light. To provide an understanding of the process by which Pc 227 and other alkyl-alkylsiloxysilicon phthalocyanines such as Pc 227 are photolyzed, bond dissociation energy, natural bond orbital (NBO) charge distribution, spin density distribution, nucleus-independent chemical shift (NICS), and electron localization function (ELF) calculations have been carried out on two models related to it. These show that the lowest energy pathway for the photolysis of Pc 227 is a homolysis involving a phthalocyanine π radical having a low SiPc-C bond dissociation energy. The promise of the results of this study for synthetic chemistry and drug development is discussed. This journal is

TOPICAL DELIVERY OF PHTHALOCYANINES

The invention relates to topical pharmaceutical compositions comprising a phthalocyanine, wherein a diamagnetic metal ion moiety is either coordinated or covalently bound to the phthalocyanine core. The invention also relates to methods for destroying cancer tissue, precancerous cells, photo-aged cells, damaged cells, or otherwise pathologic cells, or activated cells, such as lymphocytes or other cells of the immune system, or activated or inflamed tissue cells comprising topically administering to the cancer tissue or surrounding tissue an effective amount of a phthalocyanine composition.